United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride tablets, usp are indicated for the treatment of moderate to severe dementia of the alzheimer's type. memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of memantine in pregnant women. adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of memantine [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - herpes zoster infections: acyclovir capsules are indicated for the acute treatment of herpes zoster (shingles). genital herpes: acyclovir capsules are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. chickenpox: acyclovir capsules are indicated for the treatment of chickenpox (varicella). acyclovir capsules are contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - triamterene (unii: ws821z52lq) (triamterene - unii:ws821z52lq), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - this  fixed  combination  drug  is  not  indicated  for  the  initial  therapy  of  edema  or  hypertension  except  in  individuals  in  whom  the  development  of  hypokalemia  cannot  be  risked.   triamterene and hydrochlorothiazide capsules are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. triamterene and hydrochlorothiazide capsules are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked. triamterene and hydrochlorothiazide capsules may be used alone or as an adjunct to other antihypertensive drugs, such as beta-blockers. since triamterene and hydrochlorothiazide capsules may enhance the action of these agents, dosage adjustments may be necessary. the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfact

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - felbamate (unii: x72rbb02n8) (felbamate - unii:x72rbb02n8) - felbamate tablets, usp are not indicated as a first line antiepileptic treatment (see warnings ). felbamate tablets, usp are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. if these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with lennox-gastaut syndrome in children. felbamate is contraindicated in patients with known hypersensitivity to felbamate, its ingredients, or known sensitivity to other carbamates. it should not be used in patients with a history of any blood dyscrasia or hepat

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - fluocinonide (unii: 2w4a77ypan) (fluocinonide - unii:2w4a77ypan) - fluocinonide cream usp, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older [see  use  in  specific  populations  (8.4) ]. treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because the safety of fluocinonide cream for longer than 2 weeks has not been established and because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. therapy should be discontinued when control of the disease is achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. do not use more than half of the 120 g tube per week. fluocinonide cream should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. none. teratogenic effects pregnancy  category  c there are no adequate and well-controlled studies in pregnant women. therefore, fluoc

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate lotion, 0.05% is a super-high potent topical corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses only in patients 18 years of age or older. treatment should be limited to 2 consecutive weeks. for moderate to severe plaque psoriasis, treatment may be extended for an additional 2 weeks for localized lesions (less than 10% body surface area) that have not sufficiently improved after the initial 2 week treatment. any additional benefits of extending treatment should be weighed against the risk of hypothalamic-pituitary-adrenal (hpa) axis suppression before prescribing for more than 2 weeks. the total dosage should not exceed 50 g (50 ml or 1.75 fl. oz) per week. patients should be instructed to use clobetasol propionate lotion, 0.05% for the minimum amount of time necessary to achieve the desired results [see dosage and administration (2) ]. use in patients under 18 years of age is not recommended due to

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir ointment 5% is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous herpes simplex virus infections in immunocompromised patients. acyclovir ointment 5% is contraindicated in patients who develop hypersensitivity to the components of the formulation.

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. it should not be used for longer than two weeks unless directed by a physician. desonide cream, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - nystatin (unii: bdf1o1c72e) (nystatin - unii:bdf1o1c72e), triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - nystatin and triamcinolone acetonide ointment are indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment. these preparations are contraindicated in those patients with a history of hypersensitivity to any of their components.

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - nystatin (unii: bdf1o1c72e) (nystatin - unii:bdf1o1c72e) - nystatin ointment is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by candida albicans and other susceptible candida species. nystatin ointment is not indicated for systemic, oral, intravaginal or ophthalmic use. nystatin ointment is contraindicated in patients with a history of hypersensitivity to any of their components.